周四，美银证券将Hims & Hers Health, Inc. (NYSE: HIMS)的评级从买入下调至表现不佳。这一决定是对亚马逊最近进入勃起功能障碍（ED）和脱发市场的直接回应，这两个领域是Hims & Hers的主要业务板块。 美银证券的分析师解释说，Hims & Hers之所以能够保持超过80%的高毛利率，主要是因为其核心脱发和ED产品。该公司的商业模式得益于以低成本采购药品并以高价加 ...

Should you invest $1,000 in Hims & Hers Health right now? Before you buy stock in Hims & Hers Health, consider this: The ...

Hims & Hers offers personalized telehealth services, with a stock price that reflects high-growth potential. See why we ...

Hims & Hers Health, Inc. (“Hims & Hers”) (NYSE: HIMS), the leading health and wellness platform, today announced Deb Autor, ...

Hims & Hers Health, Inc. (NYSE:HIMS)的董事David B. Wells最近出售了40,000股公司A类普通股。这些股票以平均价格29.9896美元出售，交易总额约为120万美元。此次出售后，Wells直接持有156,036股。这些股票以29.97美元至30.055美元的价格区间出售。

Hims & Hers (NYSE: HIMS) is disrupting the healthcare market with its innovative patient treatment approach. Read More: Earn ...

Hims & Hers once again delivered a blowout quarter with surging revenue. Revenue soared 77% year over year to $401.6 million, ...

智通财经获悉，远程医疗平台公司Hims & Hers Health(HIMS.US)首席执行官Andrew Dudum表示，该公司正准备在2025年推出诺和诺德(NVO.US)的旧版GLP-1减肥疗法liraglutide的非专利版本。liraglutide分别以Victoza和Saxenda的形式销售，用于治疗糖尿病和肥胖症。在2024年上半年，liraglutide为这家丹麦制药商带来 ...

Shares of Hims & Hers slid after Amazon.com said it would offer cheap treatments for concerns like hair loss, skin care and ...

Shares of Hims & Hers Health slumped 15% on Thursday after Amazon.com launched a rival service that offers upfront pricing ...

Hims & Hers Health's stock dropped 25% due to Amazon’s competition. Learn why HIM stock's 38% upside and strong growth make ...